georgeclerk
- Pfizer (NYSE:PFE) said a Phase 3 study of its drug Ibrance in combination with stand-of-care therapies was found to help extend progression-free survival, or PFS, in patients with HR+, HER2+ metastatic breast cancer.
- The study, called PATINA, showed that median PFS was 44.3 months for patients treated with Ibrance in combination with anti-HER2 therapy and endocrine therapy versus 29.1 months for patients treated with anti-HER2 therapy and endocrine therapy alone.
- Overall survival, the study’s secondary endpoint, was not yet mature at the time of the analysis, according to a statement.
- The results were presented at the San Antonio Breast Cancer Symposium.
- Ibrance is already approved for the treatment of advanced or metastatic HR+, HER2- breast cancer in combination with an aromatase inhibitor or fulvestrant.